Methyl-2-oxocyclopentane carboxylate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl-2-oxocyclopentane carboxylate
• 英文别名: methyl (1S)-2-oxocyclopentane-1-carboxylate
• 化学式: C₇H₁₀O₃
• 分子量: 142.15
• InChiKey: PZBBESSUKAHBHD-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE<br/>[FR] COMPOSÉS BICYCLIQUES EN TANT QU'INHIBITEURS DE LA DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：SCHERING CORP

  公开号：WO2010107765A1

  公开（公告）日：2010-09-23

  The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below : formula (I).

  本发明涉及一种新型杂环化合物，作为二酰基甘油脂酰基转移酶（“DGAT”）抑制剂，包括所述杂环化合物的药物组合物以及利用这些化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损。本发明的一个示例化合物如下所示：式（I）。
• [EN] MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES
  申请人：ZENO MAN INC

  公开号：WO2021126316A1

  公开（公告）日：2021-06-24

  The present application discloses compounds of Formula (I). Such compounds, pharmaceutically acceptable salts and compositions thereof, are inhibitors of Mcl-1 proteins and are useful in treating diseases and conditions characterized by excessive cellular proliferation such as cancer.

  本申请公开了化合物的结构式（I）。这些化合物及其药用盐和组合物是Mcl-1蛋白的抑制剂，可用于治疗由于细胞过度增殖而表现出的疾病和情况，如癌症。
• Histone methyltransferase inhibitors
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US10829452B2

  公开（公告）日：2020-11-10

  The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. where R1, alk, R2, Z1, Z2, X, R3, R4, B, a, and b are as described herein.

  本公开提供的式(I)化合物是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗可通过抑制G9a和/或GLP治疗的疾病，如癌症和血红蛋白病（如β地中海贫血和镰状细胞病）。此外，还提供了含有此类化合物的药物组合物和制备此类化合物的工艺。 其中 R1、alk、R2、Z1、Z2、X、R3、R4、B、a 和 b 如本文所述。
• BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Schering Corporation

  公开号：EP2408766A1

  公开（公告）日：2012-01-25
• HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3356345A1

  公开（公告）日：2018-08-08